ONWARD Announces Appointment of Vivian Riefberg to Board of Directors

Get instant notifications when there’s news about your stocks. Claim your 1 week free trial StreetInsider Premium here.

EINDHOVEN, The Netherlands & LAUSANNE, Switzerland & BOSTON–(BUSINESS WIRE)–ONWARD Medical NV (Euronext: ONWD), the medical technology company developing innovative therapies to restore movement, independence and health in people with spinal cord injuries, today announced the appointment of Vivian Riefberg as a non-executive director. Ms. Riefberg will join the Board immediately and serve on its Compensation Committee. Her appointment to the Board of Directors will be submitted to shareholders for approval at the next annual general meeting.

This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20220926005494/en/

Vivian Riefberg Joins ONWARD Medical's Board of Directors (Photo: Business Wire)

Vivian Riefberg Joins ONWARD Medical’s Board of Directors (Photo: Business Wire)

“Vivian Riefberg is a proven expert in healthcare, government and strategy. I am pleased and honored to welcome her to our Board of Directors,” said Dave Marver, Chief Executive Officer. “Vivian brings extensive knowledge of the institutions we will be working with to bring our novel therapies to market, including the US Veterans Health Administration. Their experiences and insights will be invaluable as we work to create an entirely new therapeutic area of ​​neuromodulation and help people with spinal cord injuries and other movement disabilities.”

“ONWARD has the opportunity to build a very special company that is both successful and impactful,” said Vivian Riefberg. “I have had the privilege of advising many leading companies during my career. ONWARD has an opportunity to help people with spinal cord injuries using breakthrough science, technology and intellectual property, driven by a wholehearted mission.”

In 2020, Ms. Riefberg retired as a Senior Partner at McKinsey & Company, where she held various senior positions including Head of the Public Sector Practice for the Americas and Co-Head of the US Health Care Practice. She served on the Global Board of Directors of McKinsey & Company and served on the Global Partner Evaluation and Development Committee. Ms. Riefberg is currently Professor of Practice at the University of Virginia Darden School of Business, where she holds the David C. Walentas Jefferson Scholars Chair. At Darden, Ms. Riefberg focuses on healthcare, consulting and strategy across the private, public and not-for-profit sectors. Her focus is on leadership leadership, including leadership in times of uncertainty and crisis, healthcare solutions and innovation, and women’s leadership.

Also Read :  Research agenda provides a roadmap for eliminating racism in emergency medicine

Ms. Riefberg serves on the boards of directors of Signify Health, K Health and Lightrock, an impact investing firm, as well as Public Broadcasting System (PBS), Johns Hopkins Medicine, the Lorna Breen Heroes Foundation and the National Education Equity Lab. She is also an advisory board member for the Smithsonian’s proposed American Women’s History Museum. Previously, she served on the Board of Directors of the US National Institutes of Health (NIH) Clinical Center and on the NIH Advisory Board for Clinical Research. She also served on the board of directors of the Partnership for a Healthier America (PHA), a nonprofit organization formed to mobilize efforts to solve the problem of childhood obesity as a result of First Lady Michelle’s Let’s Move campaign Obama.

Ms. Riefberg is a frequent speaker at various conferences, including the World Economic Forum in Davos. She also writes for leading industry publications on improving US healthcare, government productivity and women’s leadership.

She holds a BA, magna cum laude, in History from Harvard-Radcliffe College and an MBA with honors from Harvard Business School.

Also Read :  The New York Institute of Finance (NYIF) Announces Global Partnership With Rock Orient Foundation and the American Education Center Inc.

About ONWARD Medical

ONWARD is a medical technology company developing innovative therapies to restore movement, independence and health to people living with spinal cord injuries. ONWARD’s work builds on more than a decade of basic and preclinical research conducted in the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered through implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other function in people with spinal cord injury and ultimately improve their quality of life.

ONWARD has received three Breakthrough Device Designations from the US FDA covering both ARC-IM and ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and a wireless programmer. Positive topline data was reported in September 2022 from the Company’s first pivotal study, called Up-LIFT, which evaluated the ability of ARC-EX therapy to improve upper extremity strength and function. The Company is currently preparing US and European marketing authorization applications. ARC-IM consists of an implantable pulse generator and an electrode that is placed near the spinal cord. The Company completed its first human application of the ARC-IM neurostimulator in May 2022.

ONWARD is headquartered at the High Tech Campus in Eindhoven, The Netherlands. It has extensive offices in Lausanne, Switzerland and a growing US presence in Boston, Massachusetts. For more information about the company, visit ONWD.com. To access our 2022 financial calendar, please visit IR.ONWD.com.


Certain statements, beliefs and opinions contained in this press release are forward-looking and reflect the Company’s or, as the case may be, management’s current expectations and projections of future events. By their nature, forward-looking statements involve various risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A variety of factors, including but not limited to changes in demand, competition and technology, could cause actual events, performance or results to differ materially from anticipated developments. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements contained in this press release as a result of any change in expectations or any change in the events, conditions, assumptions or circumstances any forward-looking statements are based on. Neither the Company, its advisers or agents, nor any of its affiliates, nor the officers or employees of any such person, warrants that the assumptions underlying such forward-looking statements are free from error, nor does it assume any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecast developments. You should not place undue reliance on any forward-looking statement, which speaks only as of the date of this press release.

Also Read :  C. Mondavi & Family Announces Promotion of Pam Novak to Vice President of Marketing

For corporate inquiries:

[email protected]

For media inquiries:

MC Services Ltd

USA: Laurie Doyle, phone: +1.339.832.0752

Europe: Dr. Johanna Kobler, Katja Arnold, Kaja Skorka T: +49 89 210 228 0

[email protected]

For investor inquiries:

[email protected]

Source: NEXT